NCT00934063

An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin®

A 24-month Prospective, Non-interventional, Observational Study on the Composite Clinical Endpoint (GET-Score) Reflecting Quality of Life, Body Composition and Cholesterol Metabolism in Patients Treated With Norditropin® (Somatropin)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 121 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This observational study is conducted in Europe. The aim of this observational study is to investigate the changes in a score (GET-score) which includes quality of life, body composition and cholesterol metabolism in patients on growth hormone treatment. The GET score stands for: Growth hormone deficiency and Efficacy of Treatment, and is a quantitative measurement of the efficacy of the treatment with growth hormone in adults.

Conditions

• Growth Hormone Disorder
• Adult Growth Hormone Deficiency

Interventions

Type	Name	Description
DRUG	somatropin	For s.c. (under the skin) injection. Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
OTHER	No treatment given	Control group not receiving treatment

Timeline

• Start date: 2009-07-01
• Primary completion: 2013-12-01
• Completion: 2014-06-01
• First posted: 2009-07-08
• Last updated: 2015-04-29

Locations

1 site across 1 country: Germany